For patients with mutations likely to cause AD GP130 deficiency, an accurate assessment of pathogenicity requires a detailed investigation of HIES symptoms and, ultimately, functional evaluation of the mutants using patient cells. The gene discussed is IL6ST; the disease is Alzheimer disease.